Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 689 clinical trials
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

This study is to explore the markers in early prediction of the efficacy of pre-operative pertuzumab plus trastuzumab (PH) combined with chemotherapy for early stage or locally advanced human epidermal growth factor receptor-2 (HER-2) positive primary breast cancer.

pertuzumab
primary tumor
epidermal growth factor receptor
core needle biopsy
ejection fraction
  • 0 views
  • 19 Feb, 2024
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed …

tislelizumab
measurable disease
small cell lung cancer
cisplatin
pemetrexed
  • 0 views
  • 19 Feb, 2024
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

At the same time, combined with four generations of CAR-T cells and PD1 monoclonal antibody, PD1 / PDL1 signal pathway was blocked, anti-tumor effect of CAR-T was improved, and immune response and long-term remission rate of DLBCL were improved.

ejection fraction
ct scan
flow cytometry
refractory b-cell non-hodgkin lymphoma
neutrophil count
  • 0 views
  • 19 Feb, 2024
Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

  • 0 views
  • 29 Jan, 2025
"CHOiCE"! Choose Health: Oncological Patients Cenetered Exercise

The program considers the preferences of EX of cancer survivors, giving the possibility to choose the EX modality (autonomous, with personal trainer or group class).

  • 0 views
  • 19 Feb, 2024
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)

(n=200) Phase 2: This is a randomized controlled trial to 1) quantify the effects of (i) physical therapy compared to (ii) a control group in individuals with AWS following breast cancer surgery related to physical activity and physical impairments such as lymphedema, shoulder motion, function, and pain (n=44, 22 in …

breast cancer, treatment
prophylactic
sentinel node
sentinel lymph node biopsy
mastectomy
  • 0 views
  • 19 Feb, 2024
Clinician Communication About Sexual Health

The objective of this study is to adapt a previously tested brief intervention aimed at enhancing clinicians communication about sexual health (iSHARE) to a mobile web-based platform showcasing a two-part podcast and to assess the feasibility, acceptability, and preliminary effects of the intervention in breast cancer clinicians.

  • 0 views
  • 19 Feb, 2024
Assessing the Sensitivity of "SureTouch " in Identifying Clinically Significant Masses in Women Undergoing Diagnostic and Screening Mammography

Prospective, case-control study being conducted to determine the sensitivity of the SureTouch device in detecting known masses at a pre-determined level of specificity.

screening mammography
  • 0 views
  • 19 Feb, 2024
Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study

The goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with in-breast recurrences after a previous lumpectomy and RT, investigators propose to test partial breast irradiation with the target volume encompassing the entire surgical bed with 1.0-1.5 cm margins.

breast carcinoma
metastasis
systemic therapy
carcinoma
invasive breast cancer
  • 0 views
  • 19 Feb, 2024
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer

This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB/IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.

pd-l1
non-squamous non-small cell lung cancer
carcinoma
atezolizumab
hiv test
  • 0 views
  • 19 Feb, 2024